Tag: ICI

Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:

Cancer Research Institute1

Patient Perspectives on Cancer Immunotherapy at the 2020 CRI Virtual Immunothera...

  Nov 03 2020 Tagged PATIENTS, ICI

At the 2020 CRI Virtual Immunotherapy Patient Summit, three CRI ImmunoAdvocates— cancer veterans treated with immunotherapy —share their experiences with cancer, immunotherapy, health care, and support.

Read more
Immunotherapy Web Featured Images 12

2020 CRI Virtual Immunotherapy Patient Summit: How immunotherapy works against c...

Immunotherapy is transforming treatment for many cancers and shows incredible promise for the future of all cancer care. But what is immunotherapy, and how does it work?

Read more

Immunotherapy Expert Puts Fresh Focus on AEs

  Oct 15 2020 Tagged ICI, toxicity

In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.

Read more
blood a1

Enhancing antitumor immunity through checkpoint blockade as a therapeutic strate...

  Sep 08 2020 Tagged ICI, NHL, TCL, PD-1, PD-L1

The majority of historical therapies for managing T-cell lymphomas (TCLs) have consisted of T-cell–depleting strategies. Unfortunately, these forms of therapies can hamper the ability to mount effective antitumor immune responses. Recently, the use of checkpoint inhibitors has revolutionized the therapy of solid and hematologic malignancies.

Read more
ImmunotherapyWebsite Images Featured 13

Limited evidence of tumour mutational burden as a biomarker of response to immun...

Several studies have suggested that Tumor Mutational Burden (TMB) correlates with patient response to ICB treatments 2–6, likely due to immunogenic neoantigens generated by novel mutations accumulated during cancer progression.

Read more

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

Immune checkpoint inhibitors (ICIs) commonly target CTLA-4, PD-1, and PD-L1, which promote inhibitory signals on immune effector T cells against cancer cells. Although ICIs have improved outcomes in several cancers, their use is also associated with significant adverse events (AEs), including death.

Read more
science daily

New tool identifies which cancer patients are most likely to benefit from immuno...

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed. This advance in precision medicine will allow clinicians to tailor treatments specifically to patients and avoid treatment paths that are unlikely to be successful.

Read more
nature 2

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the eff...

  Aug 24 2020 Tagged ICI, PD-L1

Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive clinical outcomes for multiple tumours.

Read more
ImmunotherapyWebsite Images Featured 3

Checkpoint Molecule Could Be New Cancer Immunotherapy Target

  Aug 21 2020 Tagged ICI

A team of researchers at the German Cancer Research Center (DKFZ) and the Berlin Institute of Health (BIH) have released new data that highlights a potential new target for cancer immunotherapies. The scientists found that the metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promoted the spread of tumor cells and suppressed the immune system.

Read more
ImmunotherapyWebsite Images Featured 1

Harnessing Stem Cell–Like T Cells to Better Fight Cancer

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

Read more